Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Rituximab in CD20+ Acute Lymphoblastic Leukemia
NCT04920968Phase 2Terminated
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Oct 2021
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in acute lymphoblastic leukemia (ALL), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Oct 2021; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04920968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920968.